Background: Intravenous lipid emulsion (ILE) is used to treat drug poisonings. The resultant hyperlipemia may affect laboratory tests but the consequences are poorly characterized. In a clinical trial we therefore investigated the effects of ILE on laboratory tests analyzed on common analytical platforms (Roche ® cobas 8000 and SYSMEX
Introduction
High-dose intravenous lipid emulsion (ILE) is used in the management of cardiovascular collapse caused by cardioactive drug poisonings -in particular poisonings with local anesthetics [1] [2] [3] [4] . ILE is now available in Denmark at all perioperative care units for the acute treatment of local anesthetic poisonings. The most common lipid emulsion used for this indication is 20% Intralipid (20% soy bean oil, glycerol and phospholipids in an emulsion) [5] . The recommended dose of ILE is not definite, but an initial bolus of 1.5 mL/kg, followed by a 0.25 mL/kg/min infusion for 30-60 min is commonly used [2] . Rapid lipid emulsion infusion results in hyperlipemia which may lead to analysis interference due to, e.g. increased sample turbidity, sample inhomogeneity and volume displacement [6, 7] . ILE-induced hyperlipemia has in addition been associated with sample hemolysis [8] [9] [10] which may further affect laboratory tests. Test failure or delayed or erroneous test results caused by ILE-induced hyperlipemia could potentially delay or misguide the treatment of the critically ill, poisoned patient [5, 7, [11] [12] [13] . In vitro experiments investigating the effects of ILE on laboratory analyses have been conducted [5, 7] showing that ILE may significantly affect levels of various analytes -depending on analyzer and assays used [14] . However, in vitro/ex vivo experiments may not be directly applicable to real patient samples [5, 14] . No clinical trials have explored the in vivo effects of an ILE dose like that recommended for drug-poisonings on laboratory analyses. Limited knowledge about this important aspect of ILE-therapy may lead to uncertainty, hence complicating patient management. We therefore investigated the acute effects of a high-dose ILE-infusion on a range of common laboratory tests in a placebo-controlled, randomized clinical trial, designed to simulate a β-blocker (metoprolol) poisoning treated with ILE in healthy trial participants.
Materials and methods

Design and settings
This randomized, investigator-and-participant-blinded, placebocontrolled, four-armed crossover trial was carried out according to the principles of the Declaration of Helsinki [15] between September 2016 and March 2017. The participants were healthy men 20-30 years of age. The primary outcome measures were the effects of ILE -compared to placebo -on metoprolol pharmacodynamics and plasma concentrations, which will be reported elsewhere. The effect of ILE on laboratory analyses was a secondary endpoint in the trial and will be reported here. 
Trial procedures
Participants were included by a blinded investigator and assigned to a randomized order of interventions corresponding to a computergenerated list produced by unblinded personnel not directly involved in the trial [16, 17] . The participants underwent four interventions on 4 days separated by a 1-week wash-out period with combinations of metoprolol (Seloken ® ), ILE (Intralipid 20%) or matching placebos (matching volumes of isotonic saline) in randomized order (placebo + ILE; metoprolol + placebo; metoprolol + ILE; placebo + placebo). The participants were fasting for 10 h before the trial days. On trial days, a venous line was inserted into each antecubital vein and the site of infusions was covered with a cloth to blind both investigator and participant. After a 15-min initial baseline period, 60 mg of metoprolol/placebo (120 mL) was administered over 30 min from baseline. At the 12.5-min time point, ILE/placebo was administered as an initial bolus (1.5 mL/kg) followed by a continuous infusion (0.25 mL/kg/min) until the 30-min time point -corresponding to approximately 330 mL in a 70-kg person. The participants were monitored for 120 min from baseline. All 10 trial participants completed 2 trial days each with ILE and 2 days each with a matching volume of saline placebo (yielding a total of 20 days with ILE and 20 days with placebo).
Analyses performed
Venous blood samples for measurements of analytes were drawn at timepoints 0 (baseline), 30, and 60 min -into lithium-heparin -or EDTA-tubes (sample dependent). Supplementary Table 1 depicts the full list of tests performed, assay kit information, test-specific L-and H-index cut-offs and analyte-specific reference change values (RCVs) calculated using the formula:
(CV I = within-subject biological variation; CV A = analytical imprecision) [18] . Samples were handled and analyzed as routine clinical samples (i.e. no specific measures were performed to reduce the lipid concentration of the samples) at the Department of Clinical Biochemistry, Copenhagen University Hospital Bispebjerg and Frederiksberg.
In the first five participants enrolled (each treated for 2 days with ILE and for 2 days with placebo in random order), the following analytes were measured: albumin (Alb) (g/L); alanine aminotransferase (ALT) (U/L); alkaline phosphatase (ALP) (U/L); aspartate aminotrans- Further, to investigate the mechanism behind the possible occurrence of intravascular hemolysis due to ILE, haptoglobin was measured after end of the trial on thawed plasma samples which were drawn at baseline and at 10, 20, 30, 40, 50, 60, 90 and 120 min into EDTA-tubes and stored at −80 °C until analysis.
Analytical procedures
White blood cell (WBC) counts were measured by flow cytometry on a SYSMEX XN-system (Sysmex Corporation Europe GmbH, Hamburg, Germany). All other analyses were performed on a cobas ® 8000 analyzer with c701 and c702 modules (Roche Diagnostics GmbH, Mannheim, Germany). In 2017, an estimated 5.6 billion tests were performed worldwide on the cobas 8000, on more than 14,000 analytical units in nearly 50 countries [19] . The cobas 8000 is an automatic system for the analysis of routine chemistry assays and immuno assays, using two-reagent procedures and dichromatic spectrophotometrymethods to reduce spectral interference effects: the cobas 8000 automatically detects lipemia using absorption at wavelengths of 660/700 nm in samples. The analyzer generates an index value for lipid interference -i.e. the L-index (a unit-less index determined by turbidity of the sample which corresponds to the concentration of lipid emulsion [Intralipid] in experimental in vitro studies) [6, 20] . Likewise, hemolysis (H) and icterus (I)-indices are automatically generated. These indices are used in autoverification for all clinical laboratory tests [21] . Linkage between the cobas 8000 and the Laboratory Information System (LIS) (LABKAII v. 3.3.1.0, DXC Denmark, Copenhagen, Denmark) [22] -which is integrated with the electronic health record (EHR) -is provided by cobas IT middleware (cITm) [23] . The cITm in our laboratory automatically flags and blocks samples with index-values above the cut-off and the results are not sent to the LIS/EHR (leading to a report failure). Instead, the terms "hemolysis" or "lipemia" are forwarded to the LIS/EHR. Automatic blockage or flagging of samples with indices above the cut-off is common practice in laboratories using both cobas 8000 [10] and other automatic analysis platforms [24] . In our laboratory, blocked results are by default stored by the cITm for 14 days. In this trial, initially blocked results were retrieved on the trial days from the cITm manually by a laboratory technician (a flow chart for the retrieval of test results is provided in Supplementary Figure 1) .
Statistics
Statistical analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 7.02 (GraphPad Software Inc., La Jolla, CA, USA). Mean differences between treatment-days were compared using a mixed model (PROC MIXED) of repeated measures with fixed (intervention, timepoint) and random (participant-ID × period)-effects. A Tukey-adjustment for multiple comparisons was performed for repeated measures of haptoglobin. We tested the intervention/time-interaction for all analytes to investigate whether mean change over time was identical on days with ILE compared to placebo. The metoprolol had no significant effects on measures of analytes. Carry-over was unlikely given the washout period. Therefore, measurements from the 2 days with ILE were averaged for each participant and compared to the corresponding 2 placebo-days, resulting in a total of 20 days with ILE and placebo, respectively. All results are presented as means ± standard deviations (SD). The differences in means between levels of analytes are presented as absolute differences with 95% confidence intervals (CIs) and the percentage differences. A two-sided p < 0.05 was considered statistically significant.
An absolute value outside the normal range for a specific test result, and a difference between ILE and placebo exceeding the RCV were considered potentially clinically significant [18] , because a difference of this size might influence clinical decision-making. Finally, we calculated frequencies of blocked test results by the cITm leading to report failure, and reasons for this report failure (Table 1) . Relative changes from baseline (percentages) on days with ILE and placebo for all investigated analytes are provided in Supplementary Figure 2 .
Results
Samples on ILE-days were clearly more lipemic compared to samples drawn on placebo-days; this could be observed visually by unblinded laboratory staff on uncentrifuged blood a few minutes after the samples were drawn.
Analytes with blocked results on ILE-days
Twelve out of 20 tests performed were invariantly blocked due to exceedance of the L-index cut-off on ILE-days. The H-index cut-off was exceeded in seven out of 20 of tests (Table 1) . On ILE-days, Alb; ALT; AST, bilirubin; carbamide; total calcium; CK and phosphate were blocked by the cITm at 30 and 60 min due to index values above either the L-or the H-index cut-off, leading to report failure (Table 1) . Total cholesterol, HDL and Na + were invariantly influenced by lipemia or hemolysis. Pancreatic amylase results were all blocked due to lipemia at time 30 min, compared to four out of 10 at 60 min. For ALP, five out of 10 (one due to hemolysis and four due to lipemia) were blocked at 30 min compared to none at 60 min. LDH was completely blocked at 30 min due to hemolysis, compared to none at 60 min. All results blocked were subsequently retrieved manually by a laboratory technician on the trial day. Reporting of WBC, CRP and triglycerides were unaffected by ILE (Table 1) . No blockage of test results, hence no report failure occurred on placebo days.
Effects of ILE compared to placebo on analyte levels
The effects of ILE on levels of the individual analytes are shown in Figures 1-4 and Table 2 . We observed no difference in baseline values between days, thus, carry-over was negligible. ILE increased triglyceride levels approximately 14 mmol/L compared to placebo (95% CI: 13.0-14.6, p < 0.0001) at 30 and 60 min -corresponding to a more than 1700% increase (Table 2 and Figure 4E ).
The mean change over time (intervention-time interaction) for total calcium, LDH, Na + , leukocytes, neutrophils and triglycerides differed significantly (p < 0.05) between days with ILE compared to placebo infusions (Table 2) .
For AST, total calcium, LDH, Na + and neutrophils, the differences between mean analyte levels on ILE-days compared to placebo-days exceeded test-specific RCVs (total calcium and Na + only at the 30-min timepoint) ( Table 2 and Figures 1-4) . This change was statistically insignificant for AST. Leukocytes and neutrophils increased gradually on ILE-days compared to placebo (34% and 53%, respectively, at 60 min [absolute values: Figure 1A ) and crea decreased 13% (11.3 mmol/L [95% CI: 19.6-9.6, p < 0.001]) ( Figure 3C ) at 30 min on ILE-days compared to placebo, whereas differences at 60 min were not statistically significant (Table 2) . Mean Na + -values were significantly decreased 4% and 2.5% from 141 to 135 and 137 mmol/L at 30 and 60 min, respectively, on ILE-days (p < 0.001) ( Figure 1C ). Mean values outside the normal ranges were observed for total calcium (2.1 mmol/L), LDH (219 U/L) and Na (Table 2) .
No statistically significant differences between ILE and placebo were observed for Alb, ALP, bilirubin, carbamide, total cholesterol, HDL, K + , pancreatic amylase, phosphate (Table 2) , nor were there any differences in plasma haptoglobin levels at any timepoint (p = 0.2-0.9) ( Figure 5 ).
Discussion
In a randomized clinical trial, we investigated the consequences of a high-rate ILE-infusion on a range of common laboratory tests. ILE caused a report failure of the majority (16 out of 20) of the tests performed, except CRP, WBCs and triglycerides. However, despite the high frequency of blockage on ILE-days, it was possible to retrieve these manually. In the retrieved results, the effects of ILE (compared to saline placebo) on measured analyte mean values were marginal for most investigated tests: values outside the normal range were observed only for total calcium, LDH and Na
In vitro/ex vivo experiments have previously shown that analytical interferences caused by ILE significantly affected the levels of various analytes [7] . ILE may affect biochemical tests in numerous ways (increased turbidity and light scattering, sample inhomogeneity [14] , pipetting disruption [5, 7, 10] , volume displacement [6, 7] and hemolysis [8] [9] [10] ). Lipemic samples absorb light from 300 to 700 nm. Therefore, photometric methods within these wavelengths are especially affected by lipemia due to light scattering [25] . This agrees with our observations: most of the tests performed using absorption-photometric methods were blocked due to exceedance of either L-or H-index cut-offs. However, we observed that blockage of results was not necessarily associated with neither statistically nor clinically significant bias caused by ILE (e.g. Alb, bilirubin, phosphate and carbamide).
The explanation for this apparent discrepancy between the frequency of blockage of test results and marginal effects on several analytes is not entirely clear. Of note, the use of a universal L-index has previously been questioned [6, 14] because it may not be applicable to physiological hyperlipemia: previous experiments have shown that for several assays, interference was not observed in Intralipid-supplemented patient samples with similar or higher L-indices or triglyceride levels compared to native patient samples -likely due to a lack of high-order lipid-protein complexes in ILE [14] . ILE-induced in vivo (hyper)lipemia and in vitro sample hyperlipemia are different situations, which may explain our findings; particularly grades of lipid integration into chylomicrons and endogenous clearance of triglycerides by lipoprotein lipase-induced triglyceride hydrolyzation [26] are important. These factors may affect the distribution and physiochemical properties of ILE -and thus assay interference effects -in the circulation compared to in vitro-experiments. The exact composition and physiochemical properties of ILE in the circulation in humans is however undefined.
A practical method to manage ILE-induced sample hyperlipemia -balancing result reliance and urgent patient care -is crucial. Overt wrong results may potentially misguide treatment. It is therefore reasonable to routinely block hyperlipemic samples if specific L-(or H-) indices are exceeded and clinically significant bias could affect results [18] . In addition, it would be against the CEaccreditation of the test if samples are analyzed after the equipment has detected sample lipemia. Thus, our data support that ideally, samples should be drawn prior to ILE-infusion. Furthermore, postponement of phlebotomy would be commendable as fewer samples were blocked at 60 min compared to 30 min. On the other hand, as patients receiving ILE are critically ill, clinicians may need information on blood parameters for optimal monitoring and treatment. Our study -which suggests that for some analyses the result may be relied upon -therefore provides important information on which parameters can potentially be measured at lipemia-levels above those stated by manufacturers. This could be used in the laboratories to test the effect of higher degrees of lipemia on the individual parameters, and -in case no interference is detected -include this in the validation of the analyte, thereby keeping the analysis accreditation. Alternatively, if in the interest of the critically ill patient, the laboratory might choose to release the result to the clinician in situations where knowledge of the result is required for correct and timely patient care. In such situations, knowledge of the in vivo interference of the lipemia will be important for that decision, which is usually made by medical professionals in the clinical chemistry department. If results are released they should be flagged (e.g. "hemolysis" or "lipemia", along with information on the direction of potential bias).
When high-dose ILE has been administered, it would be advisable to consult the laboratory prior to ordering of biochemical analyses. This would allow the clinician and laboratory to take precautions regarding time of sampling and measures to handle hyperlipemia. It is important to emphasize that other relevant acute biochemical tests not investigated here may also be affected by ILE, e.g. coagulation status [27] , troponins, CKMB and blood gas analyses [7] .
An increase in the lipid content in a blood sample is correlated with hemolysis [10] . The exact underlying mechanism is unknown, but intravascular hemolysispossibly due to the lecithin-content of the emulsion -has been proposed [8] . Free, unbound hemoglobin binds to haptoglobin with high affinity, leading to a decline in haptoglobin levels. Thus, plasma haptoglobin acts as a marker of intravascular hemolysis. A previous study found that the plasma haptoglobin concentration would be expected to decrease by approximately 0.2 g/L after 2 h [28] . However, despite H-index values above the cut-off in seven out of 20 tests performed, there were no differences in the levels of haptoglobin on ILE-days compared to placebo. This indicates that ILE-induced hemolysis primarily occurs in the vacutainer-tubes after sampling -in line with previous findings [8] . Percentage difference between means on days with ILE compared to saline at the 60-min timepoint. 
Limitations
We used a single ILE-dose corresponding to a total dose of approximately 400 mL (mean weight of participants was 73.4 kg). This is smaller than that often administered in cases of severe drug poisonings [2] . We performed our study using healthy participants with baseline measures within the normal range. In comparison, analyte levels are often much outside normal ranges in real-life poisoning scenarios due to the clinical status of the critically ill patient. This limits the generalizability of this trial. Analyzing effects of ILE on laboratory samples was a secondary endpoint of this study and no powercalculations have been performed for these endpoints. Our study may thus be underpowered to detect small differences in measures of analytes. However, as we observed few values outside the normal range, differences that would reach statistical significance in a larger trial would still be clinically irrelevant. Our study was not designed to investigate the mechanistic effects of ILE on analyte levels. Thus, we are not able to definitely conclude whether effects on, e.g. LDH, liver parameters and leukocytes were due to the physiological consequences of the ILE [26] or due to sample interference. The mechanistic effects of ILE on laboratory analyses in vivo could be a focus for further clinical studies. We only included male volunteers, which may also limit generalizability 
<0.0001
Changes in levels of analytes caused by a rapid infusion of ILE (1.5 mL/kg + 0.25 mL/kg/min for 15 min) to the 30-min timepoint.
a The intervention-time-interaction tests the hypothesis that mean change over time on ILE-days compared to placebo-days at all follow-up times was identical. Thus, a p-value >0.05 means that ILE had no statistically significant effects on the laboratory result compared to placebo. Mean outside the normal range. Alb, albumin; ALT, alanine transaminase; ALP, alkaline phosphatase; AST, aspartate transaminase; CK, creatine kinase; crea, creatinine; HDL, high-density lipoprotein; K + , potassium; LDH, lactate dehydrogenase; Na + , sodium. CRP is not presented in this table (no changes were observed). because of possible gender differences in levels of analytes. Finally, as the effect of lipemia on laboratory tests depends on the platform and assays used [7, 14] our methods and results may therefore only be reliable if applied on similar assays.
Strengths
The strength of this study is the randomized, placebocontrolled, cross-over design. This reduces overall biological variation ensuring that effects observed on the analyses performed were indeed caused by the ILE. Our experimental design also reduces risk of false interference due to other causes of increased turbidity, which has been argued a disadvantage of automatic L-index determination methods [10] . Therefore, our study provides reliable data on effects of ILE on common laboratory analyses in vivo in humans. The dosing regimen was chosen to simulate the dose of ILE used for drug poisonings and lipemic blood was sampled at time points where an acute biochemical profile would likely influence patient management. The ILE infusion led to triglyceride concentrations above 14 mmol/L -this magnitude of hyperlipemia is not routinely investigated by manufacturers [7] . The samples were handled according to standard protocols, and no measures were taken to reduce sample lipemia. Thus, our data could be used to optimize the sampling schedule and correct retrieval of biochemical data in a clinical situation where a large amount of ILE has been administered to the critically ill, poisoned patient. In this situation, report failure or overt erroneous laboratory values may have serious consequences for patient management [12, 13] .
Conclusions
We observed that a high-rate ILE-infusion caused a report failure of most laboratory tests performed on a cobas 8000 analysis platform, but not on a SYSMEX XN-system. Ideally, phlebotomy should be performed prior to ILEadministration. Our results indicate that postponement of phlebotomy is advisable when ILE has been administered, as the effects on analyses by ILE were reduced at the 60-min timepoint compared to the 30-min timepoint.
Even though nearly all test results were not forwarded to the EHR due to exceedance of L-or H-index cut-offs, clinically significant bias was observed for AST, total calcium, LDH, Na + and neutrophils. Most analytes -particularly ALP, bilirubin, carbamide and phosphate -were marginally affected by ILE. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication. Trial registration: ClinicalTrials.gov ID: NCT02924454.
